Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Meningioma × regorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 39 Carcinoma, Hepatocellular 15 Rectal Neoplasms 8 Neoplasm Metastasis 8 Colonic Neoplasms 7 Gastrointestinal Stromal Tumors 6 Ovarian Neoplasms 5 Sarcoma 4 Melanoma 4 Osteosarcoma 3 Glioblastoma 3 Cholangiocarcinoma 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Liver Neoplasms 2 Gallbladder Neoplasms 2 Fatigue 2 Esophageal Neoplasms 2 Colorectal Cancer Metastatic 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1 Thyroid Neoplasms 1 Thymoma 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1 Solid Malignant Tumors 1 Small Cell Lung Carcinoma 1 Rhabdomyosarcoma 1

Interventions

Hydroxyurea 7 Everolimus 6 lutetium Lu 177 dotatate 5 Bevacizumab 5 Magnetic Resonance Spectroscopy 4 pembrolizumab 3 abemaciclib 3 Sunitinib 3 Imatinib Mesylate 3 gallium Ga 68 dotatate 2 arginyllysine 2 aldesleukin 2 Whole Body Imaging 2 Specimen Handling 2 Radiotherapy 2 Octreotide 2 Nivolumab 2 Cyclophosphamide 2 Amino Acids 2 90Y-octreotide, DOTA-Tyr(3)- 2 vistusertib 1 vatalanib 1 tozuleristide 1 sargramostim 1 regorafenib 1 pasireotide 1 olaparib 1 neratinib 1 fludarabine phosphate 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06275919 2025-03-13

MIRAGE

Istituto Oncologico Veneto IRCCS

Phase 2 Recruiting

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡